<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18252">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01818310</url>
  </required_header>
  <id_info>
    <org_study_id>2012-T2DM-CLI</org_study_id>
    <secondary_id>2012-001825-28</secondary_id>
    <nct_id>NCT01818310</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Autologous Bone Marrow Aspirate Concentrate for No-Option Critical Limb Ischemia</brief_title>
  <acronym>DIALEG</acronym>
  <official_title>Randomised Clinical Study of Safety and Efficacy of Autologous Bone Marrow Aspirate Concentrate (BMAC) for No-option_critical Limb Ischemia in Type-II Diabetes Mellitus Patients. (DIALEG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regional Council of the Moravian-Silesian region, KU MSK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Czech Republic: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the presented clinical trial is to evaluate a hypothesis, that BMAC prepared from
      bone marrow aspirate and injected intramuscularly into ischemic areas of the lower extremity
      in patients with diabetes mellitus type II., intraarterially into the defect of the limb or
      with an intravenous application only, has a greater potential to improve the perfusion in
      the ischemic limbs than standard treatment of NO-CLI. Another aim of the study is to find
      out differences among three different therapeutic types of BMAC application, to define their
      effectiveness and safety and to compare the impact of different means of application to the
      speed of healing of the limb defects and the improvement of perfusion parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary hypothesis assumes, that the intravenous application of BMAC in patients with T2DM
      older than 30 years of age, with a dose of insulin exceeding 0.7 U/kg/day or 50U/day will
      result in decreasing the insulin dose in the course of 6-month follow-up and in an
      improvement of the glycHBA1c levels, improvement of the liver and kidney function, decrease
      of the cholesterol levels and improvement of the immune response parameters, i.e. parameters
      of lymphocytar blastic transformation, more than in case of patients with intramuscular or
      intraarterial application of BMAC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Amputation-free survival</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The data for Primary outcome will be collected throughout the first 18 months of the study. The assessed parameters will include amputation-free survival in order to verify the safety and efficacy of the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tissue perfusion parameters</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The efficacy of BMAC application will be evaluated throughout the whole course of the clinical trial, with final assessment at the end of the trial.
Increase of the monitored parameters of the tissue perfusion measured with LDP-Periflux 5000 (Perimed), i.e. increase of the ABI - ankle-brachial index, TP - toe pressure, TBI- Toe Brachial index and TcpO2- transcutaneous oxygen pressure.
Decrease of the SPP perfusion parameter - skin perfusion pressure reflecting an inflammatory activity of the affected limb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome classification</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The efficacy of BMAC application will be evaluated throughout the whole course of the clinical trial, with final assessment at the end of the trial.
- Improvement of the Rutherford scale of CLI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional angiogenesis imaging outcome</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The efficacy of BMAC application will be evaluated throughout the whole course of the clinical trial, with final assessment at the end of the trial.
- Increase of the number and quality of newly created vessels measured according to digital subtraction angiography (DSA) or MR-angiography (in allergic patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life outcome</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The efficacy of BMAC application will be evaluated throughout the whole course of the clinical trial, with final assessment at the end of the trial.
Measurable decrease of pain measured on the scale and QOL questionnaire (RAND-36).
Healing of the defect or gangrene (size and state of the wound)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in lymphocyte subsets and levels of inflammatory and antiinflammatory cytokines in each of the groups.</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immune response of study subjects will be monitored following the transplantation of stem cells, together with the periphery lymphocyte function (T-cells, B-cells, NK-cells).
Immune response parameters, (i.e. parameters of lymphocytar blastic transformation)</description>
  </other_outcome>
  <other_outcome>
    <measure>Metabolic response</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The following laboratory parameters throughout the clinical trial:
liver and kidney function
lipid spectra</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood glucose and pancreatic function response</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The following parameters will be monitored in the study subjects:
glycHBA1c levels
C-peptide</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Critical Lower Limb Ischemia</condition>
  <condition>Type-2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group A: Intramuscular</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.
The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Intraarterial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: Intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: Control-standard treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group D: Control Group Study subjects in Group D will receive a standard treatment for NO-option CLI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Group A: Intramuscular</intervention_name>
    <description>Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.
The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes.</description>
    <arm_group_label>Group A: Intramuscular</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Group B: Intraarterial</intervention_name>
    <description>Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.</description>
    <arm_group_label>Group B: Intraarterial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Group C: Intravenous</intervention_name>
    <description>Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.</description>
    <arm_group_label>Group C: Intravenous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Group D: Surgical endovascular treatment with maximum medicamentous treatment</intervention_name>
    <description>Group D: Control Group Control Group - no experimental intervention, standard endovascular treatment or bypass surgery or maximum medicamentous treatment</description>
    <arm_group_label>Group D: Control-standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes mellitus

          -  diagnosis of critical limb ischemia

          -  non-healing defect on the study limb

          -  ABI value &lt; 50 mmHg or ABI&lt; 0.4

          -  TBI value &lt; 40 mmHg or TBI &lt; 0.4

          -  TcPO2 &lt; 20 mmHg in supine position

          -  no other suitable surgical or re-vascularization procedure

          -  age &gt; 18 years

          -  signed Informed Consent

        Exclusion Criteria:

          -  non-signing of the Informed Consent

          -  anticipated life expectancy &lt; 6 months

          -  history of bone-marrow disease

          -  renal failure or dialysis dependency

          -  known malignant disease

          -  health risks excluding the possibility of general anaesthesia or sedation

          -  life-threatening ischaemic heart disease

          -  vast necrosis of the index limb

          -  active infectious disease, or ATB treatment

          -  treatment with immunosupressives

          -  pregnancy, breastfeeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vaclav Prochazka, MD, PhD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ostrava</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vaclav Prochazka, MC, PhD, MSc</last_name>
    <phone>+42059737</phone>
    <phone_ext>2544</phone_ext>
    <email>angio@vol.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katerina Vitkova, RNDr</last_name>
    <phone>+42059737</phone>
    <phone_ext>2052</phone_ext>
    <email>katerina.vitkova@fno.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaclav Prochazka, MD, PhD, MSc</last_name>
      <phone>+42059737</phone>
      <phone_ext>2544</phone_ext>
      <email>angio@vol.cz</email>
    </contact>
    <contact_backup>
      <last_name>Katerina Vitkova, RNDR.</last_name>
      <phone>+42059737</phone>
      <phone_ext>2052</phone_ext>
      <email>katerina.vitkova@fno.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Frantisek Jaluvka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaromir Gumulec, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <reference>
    <citation>Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg. 1999 Jun;12(2):123-37. Review.</citation>
    <PMID>10777239</PMID>
  </reference>
  <reference>
    <citation>Clair DG, Dayal R, Faries PL, Bernheim J, Nowygrod R, Lantis JC 2nd, Beavers FP, Kent KC. Tibial angioplasty as an alternative strategy in patients with limb-threatening ischemia. Ann Vasc Surg. 2005 Jan;19(1):63-8.</citation>
    <PMID>15714369</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 21, 2013</lastchanged_date>
  <firstreceived_date>September 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemia</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>bone marrow aspirate concentrate (BMAC)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
